Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SURG Stock Summary
Top 10 Correlated ETFs
SURG
In the News

7 Stocks With 1,000% Upside Potential
While market advocates will wince at accusations that investing is nothing more than legalized gambling, for these stocks with massive upside potential, I for one will have to concede that only speculators should read ahead. Though these enterprises may have yield lifechanging returns, they can quickly leave you in the poor house.

1606 Corp inks product distribution deal with SurgePays
1606 Corp announced that it has completed a distribution deal with Nasdaq-listed SurgePays, Inc, in which SurgePays has agreed to distribute 1606 Corp's Hemp smokable products to its thousands of registered retail store customers. The acquisition-based CBD company said SurgePays has already taken possession of 1,000 six-pack displays and is currently distributing them to registered retail store customers, along with 1606's CBD Singlz brand.

SurgePays, Inc. (SURG) Q4 2022 Earnings Call Transcript
SurgePays, Inc. (NASDAQ:SURG ) Q4 2022 Earnings Conference Call March 30, 2023 5:00 PM ET Company Participants Brian Prenoveau - Investor Relations Brian Cox - President and Chief Executive Officer Tony Evers - Chief Financial Officer Conference Call Participants Michael Diana - Maxim Group Ed Woo - Ascendiant Capital Operator Greetings and welcome to the SurgePays Inc. Fourth Quarter and 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

SurgePays Announces 2022 Preliminary Financial Results and Schedules Fourth Quarter and Full Year 2022 Earnings Call
Q4 Positive Cash Flow over $2 million with sales over $35 million Q4 Positive Cash Flow over $2 million with sales over $35 million

A Virtuous Cycle At SurgePays
The company has removed bottlenecks from its already triple-rate subscriber growth of its mobile broadband business, setting it up for a significant acceleration. It will also use that business to expand its network of partner community shops as this is easy money for prospective shops.

Cheap Stocks To Buy: Should You Watch These 5 Growth Stocks?
On Tuesday, Aveo shares soared 42% in massive volume on news that it will get acquired by South Korea's LG Chem. The post Cheap Stocks To Buy: Should You Watch These 5 Growth Stocks?

3 Stock Bets For 2023
Here are three stocks that, for various reasons, could produce outside returns in 2023. While neither of these is risk-free, we think that the upside potential of each is well worth taking a position (which we have in all three for our marketplace).

PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week
We're checking in on the top short squeeze stocks to watch this week as traders continue to have an interest in this part of the market! Short squeeze stocks are often subject to volatility with massive gains.

SurgePays Keeps Growing
Revenues up 149%, following subscriber growth but the bottom line isn't yet improving as a result of upfront costs (the tablets, sales commissions, etc.) keep increasing. New financing based on government receivables is as good as done, should remove a bottleneck as they can pre-finance more tablets.

SurgePays, Inc. (SURG) Q3 2022 Earnings Call Transcript
SurgePays, Inc. (NASDAQ:SURG ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Brian Prenoveau – Investor Relations Brian Cox – President and Chief Executive Officer Tony Evers – Chief Financial Officer Conference Call Participants Michael Diana – Maxim Group Ed Woo – Ascendiant Capital Jeff Kone – The Wall Street Resource Operator Good day, and welcome to the SurgePays Incorporated Third Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.
SURG Financial details
SURG Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 9.34 | 13.38 | 25.49 | 11.65 | 9.81 | |
Net income per share | -0.94 | -4.9 | -5.84 | -2.58 | -0.01 | |
Operating cash flow per share | -0.62 | -3.4 | -2.03 | -3.49 | 0.06 | |
Free cash flow per share | -0.62 | -3.51 | -2.03 | -3.5 | 0.01 | |
Cash per share | 0.27 | 0.18 | 0.32 | 1.43 | 0.57 | |
Book value per share | -1.22 | -2.44 | -5.03 | 0.81 | 0.4 | |
Tangible book value per share | -1.79 | -5.37 | -7.36 | -0.17 | 0.02 | |
Share holders equity per share | -1.22 | -2.44 | -5.03 | 0.81 | 0.4 | |
Interest debt per share | 0.86 | 4.54 | 5.18 | 3.47 | 0.81 | |
Market cap | 31M | 28.86M | 12.59M | 8.85M | 81.31M | |
Enterprise value | 31.81M | 37.01M | 19.59M | 10.25M | 82.39M | |
P/E ratio | -20.11 | -3.06 | -1.01 | -0.78 | -546.27 | |
Price to sales ratio | 2.03 | 1.12 | 0.23 | 0.17 | 0.67 | |
POCF ratio | -30.52 | -4.42 | -2.91 | -0.58 | 102.5 | |
PFCF ratio | -30.52 | -4.27 | -2.91 | -0.58 | 858.73 | |
P/B Ratio | -15.59 | -6.14 | -1.17 | 2.49 | 16.29 | |
PTB ratio | -15.59 | -6.14 | -1.17 | 2.49 | 16.29 | |
EV to sales | 2.09 | 1.44 | 0.36 | 0.2 | 0.68 | |
Enterprise value over EBITDA | -23.69 | -5.32 | -4.63 | -1.4 | 44.24 | |
EV to operating cash flow | -31.32 | -5.67 | -4.53 | -0.67 | 103.86 | |
EV to free cash flow | -31.32 | -5.47 | -4.52 | -0.67 | 870.09 | |
Earnings yield | -0.05 | -0.33 | -0.99 | -1.28 | 0 | |
Free cash flow yield | -0.03 | -0.23 | -0.34 | -1.73 | 0 | |
Debt to equity | -3.05 | -3.12 | -1.68 | 4.49 | 5.79 | |
Debt to assets | 1.49 | 1.47 | 2.46 | 0.82 | 0.85 | |
Net debt to EBITDA | -0.61 | -1.17 | -1.65 | -0.19 | 0.58 | |
Current ratio | 0.64 | 0.51 | 0.08 | 1.39 | 1.17 | |
Interest coverage | -10.93 | -29.88 | -2.48 | -0.8 | 0.45 | |
Income quality | 0.66 | 0.77 | 0.4 | 1.13 | -1.43 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0.42 | 0.17 | 0.21 | 0.1 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.23 | 0.56 | 0.68 | 0.22 | 0.14 | |
Capex to operating cash flow | 0 | 0.03 | 0 | 0 | -0.88 | |
Capex to revenue | 0 | -0.01 | 0 | 0 | -0.01 | |
Capex to depreciation | 0 | -0.8 | 0 | -0.06 | -0.71 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0 | 0 | 0 | |
Graham number | 5.09 | 16.41 | 25.69 | 6.86 | 0.33 | |
ROIC | 27.47 | -1.63 | 7.14 | -0.72 | 0.02 | |
Return on tangible assets | -0.49 | -2.17 | -5.34 | -0.74 | -0.01 | |
Graham Net | -2.88 | -6.23 | -7.96 | -1.15 | -0.75 | |
Working capital | -1.73M | -3.48M | -14.05M | 3.89M | 4.1M | |
Tangible asset value | -2.92M | -10.34M | -15.72M | -748.95K | 284.31K | |
Net current asset value | -3.01M | -11.11M | -16.8M | -2.06M | -1.32M | |
Invested capital | -0.63 | -1.81 | -0.71 | 2.16 | 1.63 | |
Average receivables | 651.84K | 2.19M | 1.76M | 1.82M | 6.24M | |
Average payables | 1.87M | 3.95M | 5.99M | 3.67M | 3.76M | |
Average inventory | 0 | 0 | 89.15K | 2.27M | 7.77M | |
Days sales outstanding | 29.87 | 44.41 | 2.64 | 23.23 | 27.72 | |
Days payables outstanding | 138.59 | 83.34 | 51.61 | 0 | 25.37 | |
Days of inventory on hand | 0 | 0 | 1.25 | 35.44 | 37.78 | |
Receivables turnover | 12.22 | 8.22 | 138.4 | 15.71 | 13.17 | |
Payables turnover | 2.63 | 4.38 | 7.07 | 0 | 14.38 | |
Inventory turnover | 0 | 0 | 291.28 | 10.3 | 9.66 | |
ROE | 0.78 | 2.01 | 1.16 | -3.18 | -0.03 | |
Capex per share | 0 | -0.12 | 0 | -0.01 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
Revenue per share | 1.75 | 2.28 | 2.91 | 2.92 | 2.46 | |
Net income per share | -0.1 | -0.04 | -0.12 | 0.25 | 0.32 | |
Operating cash flow per share | -0.28 | 0.01 | -0.06 | 0.38 | 0.2 | |
Free cash flow per share | -0.28 | -0.01 | -0.04 | 0.35 | 0.19 | |
Cash per share | 0.29 | 0.71 | 0.63 | 0.57 | 0.63 | |
Book value per share | 0.2 | 0.17 | 0.05 | 0.4 | 0.7 | |
Tangible book value per share | -0.15 | -0.21 | -0.33 | 0.02 | 0.37 | |
Share holders equity per share | 0.2 | 0.17 | 0.05 | 0.4 | 0.7 | |
Interest debt per share | 0.69 | 1.17 | 1.16 | 0.69 | 0.52 | |
Market cap | 49.22M | 59.26M | 56.62M | 81.31M | 63.45M | |
Enterprise value | 53.89M | 64.29M | 62.49M | 82.39M | 61.81M | |
P/E ratio | -10.15 | -33 | -9.19 | 6.68 | 3.49 | |
Price to sales ratio | 2.33 | 2.12 | 1.57 | 2.24 | 1.82 | |
POCF ratio | -14.81 | 337.68 | -70.51 | 17.14 | 22.14 | |
PFCF ratio | -14.76 | -475.9 | -112.97 | 18.67 | 23.42 | |
P/B Ratio | 20.62 | 27.9 | 89.61 | 16.29 | 6.44 | |
PTB ratio | 20.62 | 27.9 | 89.61 | 16.29 | 6.44 | |
EV to sales | 2.55 | 2.3 | 1.73 | 2.27 | 1.78 | |
Enterprise value over EBITDA | -61.22 | -105.37 | -83.05 | 20.07 | 12.32 | |
EV to operating cash flow | -16.21 | 366.34 | -77.83 | 17.37 | 21.57 | |
EV to free cash flow | -16.16 | -516.29 | -124.7 | 18.92 | 22.82 | |
Earnings yield | -0.02 | -0.01 | -0.03 | 0.04 | 0.07 | |
Free cash flow yield | -0.07 | 0 | -0.01 | 0.05 | 0.04 | |
Debt to equity | 6.47 | 12.86 | 52.07 | 5.79 | 3.1 | |
Debt to assets | 0.87 | 0.93 | 0.99 | 0.85 | 0.75 | |
Net debt to EBITDA | -5.31 | -8.24 | -7.81 | 0.26 | -0.33 | |
Current ratio | 1.39 | 1.07 | 1 | 1.17 | 1.33 | |
Interest coverage | -6.19 | -1.4 | -1.46 | 7.18 | 24.46 | |
Income quality | 2.67 | -0.2 | 0.46 | 1.42 | 0.63 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.16 | 0.1 | 0.08 | 0.08 | 0.08 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.23 | 0.16 | 0.14 | 0.14 | 0.12 | |
Capex to operating cash flow | 0 | -1.71 | -0.38 | -0.08 | -0.05 | |
Capex to revenue | 0 | -0.01 | 0.01 | -0.01 | 0 | |
Capex to depreciation | -0.06 | -1.49 | 0.97 | -1.39 | -0.57 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.01 | |
Graham number | 0.67 | 0.38 | 0.38 | 1.49 | 2.25 | |
ROIC | -0.26 | 0.31 | -2.56 | 0.26 | 0.29 | |
Return on tangible assets | -0.09 | -0.02 | -0.05 | 0.1 | 0.13 | |
Graham Net | -0.52 | -0.78 | -1.06 | -0.75 | -0.48 | |
Working capital | 3.49M | 1.42M | 53.23K | 4.1M | 8.57M | |
Tangible asset value | -1.78M | -2.6M | -4.15M | 284.31K | 5.19M | |
Net current asset value | -3.04M | -4.57M | -5.91M | -1.32M | 3.63M | |
Invested capital | 3.4 | 6.47 | 21.8 | 1.63 | 0.73 | |
Average receivables | 4.45M | 6.98M | 8.9M | 9.35M | 9.44M | |
Average payables | 3.51M | 10.25M | 15.35M | 12.37M | 7.56M | |
Average inventory | 3.72M | 4.38M | 7.58M | 10.34M | 13.35M | |
Days sales outstanding | 24.03 | 26.75 | 23.56 | 22.93 | 25 | |
Days payables outstanding | 34.11 | 46.99 | 45.27 | 22.92 | 25.29 | |
Days of inventory on hand | 14.96 | 19.79 | 24.94 | 34.12 | 51.58 | |
Receivables turnover | 3.75 | 3.36 | 3.82 | 3.92 | 3.6 | |
Payables turnover | 2.64 | 1.92 | 1.99 | 3.93 | 3.56 | |
Inventory turnover | 6.02 | 4.55 | 3.61 | 2.64 | 1.74 | |
ROE | -0.51 | -0.21 | -2.44 | 0.61 | 0.46 | |
Capex per share | 0 | -0.02 | 0.02 | -0.03 | -0.01 |
SURG Frequently Asked Questions
What is SurgePays, Inc. stock symbol ?
SurgePays, Inc. is a US stock , located in Bartlett of Tn and trading under the symbol SURG
What is SurgePays, Inc. stock quote today ?
SurgePays, Inc. stock price is $7.91 today.
Is SurgePays, Inc. stock public?
Yes, SurgePays, Inc. is a publicly traded company.